NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.362) was uploaded to the NHS England Website on Friday 9, May 2025.
The following changes have been introduced:
Elacestrant monotherapy (ELAC1)
For the treatment of oestrogen receptor- positive, HER2-negative, locally advanced or metastatic breast cancer in patients previously treated with at least 12 calendar months of therapy with a CDK4/6 inhibitor-based combination where the following criteria have been met
Moved into routine commissioning - section B of list
Pembrolizumab monotherapy (PEMB31)
Pembrolizumab monotherapy for adjuvant treatment after complete tumour resection in adult patients with UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer and whose disease has not progressed on recently completed adjuvant platinum- based chemotherapy where the following criteria have been met
Moved into routine commissioning - section B of list
Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine (BRE15)
For treating adult patients with previously untreated stage III or IV Hodgkin lymphoma where the following criteria have been met
Date moving into routine commissioning updated
Osimertinib in combination with pemetrexed and platinum- based chemotherapy (OSI4)
Osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first line treatment of adult patients with recurrent or locally advanced or metastatic non-small cell lung cancer exhibiting epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations where the following criteria have been met
Date moving into routine commissioning updated